Vera Therapeutics announced that it has completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept in patients with IgAN. The enrollment of 200 participants in this initial cohort of the trial will provide data for the 36-week UPCR primary efficacy endpoint, supporting the subsequent submission for regulatory approval.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- JPMorgan ups Vera Therapeutics target, adds Analyst Focus List
- Vera Therapeutics price target lowered to $62 from $65 at JPMorgan
- Vera Therapeutics expects cash to fund operations through atacicept approval
- Vera Therapeutics reports Q2 EPS (62c), consensus (56c)